P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be? by McElrath J, Corey L, Li F, Self S

Cell free HIV-1 virus can infect inner and outer foreskin polarized explants by Lemos MP, Perez ML, Sanchez J, Lama J, Montano S, McElrath J

Effective Antiviral CD8+T Cells Responses Are Rare in HIVPositive Step and Phambili Study Participants but Are Targeted to Low Entropy Viral Epitopes by Hancock, G, Yang, H, Mcmichael, A, Frahm, N, McElrath, J, Dorrell, L

P08-06 LB. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial by Frahm N, Geraghty DE, Casimiro DR, McElrath J, Cirulli ET, Shianna KV, Fellay J, Goldstein DB

0A07-01. HIV-specific CD8⁺T-cells of vaccinees exhibit proliferative and cytotoxic capacities comparable to those of progressors by McElrath J, Duerr A, Joshi RP, Compton AA, Berkley AM, Migueles SA, Rood JE, Connors M

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting by Spearman P, Tomaras G, Montefiori D, Huang Y, Ahmed H, Elizaga M, Hural J, McElrath J, Ouedraogo L, Pensiero M, Butler C, Kalams S, Overton ET, Barnett S, Group N

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles by Goepfert P, Elizaga M, Montefiori D, Hural J, DeRosa S, Tomaras G, Seaton K, Sato A, Ouedraogo L, Donastorg Y, Cardinali M, Lama J, Baden L, Keefer M, McElrath J, Kalams S, Robinson H